Novartis V59P13: A Phase III, Randomized, Ovserver-blind, Controlled, Multi-Center Study to Evaluate the Lot to Lot Consistency of Novartis Meningococcal ACWY Conjugate Vaccine when One Dose is Administered to Healthy Adolescents 11-18 Years of Age and t

Project: Other project

StatusFinished
Effective start/end date2/10/073/31/15

Funding

  • Novartis Pharmaceuticals Corporation: $157,680.00